Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,224.1
19.5 (0.61%)

 

  • STI Straits Times Index
    3,224.1
    19.5 (0.61%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,583.3
    -0.9 (-0.05%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,597.2
    -441.1 (-1.69%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,559.2
    -38.4 (-1.07%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    29,098.2
    -7.8 (-0.03%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,608.3
    -48.6 (-0.73%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,027.6M
  • Value: 618.1M
  • Rise: 175
  • Fall: 120
  • Unch: 456

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Tritech0.027+0.004
Koh Eco0.069+0.012
Raffles Edu0.069+0.010
Vividthree0.070+0.025
Boldtek0.114+0.005
GKE0.146+0.007
ThaiBev0.725+0.010
Zhongxin Fruit0.052+0.007
Progen0.054+0.003
Hatten Land0.062-0.001

World Indices

World Indices
Name Last Change
Nasdaq 15,235.7 +9.0
HSI 25,592.9 -445.4
HSCEI 9,081.5 -177.9
Jakarta 6,608.8 -48.1
Nikkei 225 29,098.2 -7.8
SSE Comp 3,560.9 -36.8
Shanghai A 3,731.9 -38.6
Shanghai B 276.1 -1.2
KOSPI 3,025.5 -23.6

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Hyphens Pharma HYPHENS PHARMA INTL LIMITED
Quotes 10 Minutes Delayed. Updated at 27 Oct 2021 13:09
Last (SGD): 0.300 Change: +0.005 High: 0.300 Remarks: -
Change (%): +1.69 Low: 0.300
Open 0.300 Yesterday's Close 0.295
Buy Price 0.295 Sell Price 0.300
Buy Volume ('000) 3.2 Sell Volume ('000) 73.8
Cumulative Volume ('000) 1.0 Cumulative Value 300
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 0.02051 Trailing EPS (SGD) e 0.02062 NAV (SGD) b 0.1651
PE a 14.627 Trailing PE f 14.546 Price / NAV b 1.8171
Dividend (SGD) d 0.006200 Cash In Hand (SGD) g 0.1029 Issued & Paid-up Shares c 300,430,000
Dividend Yield (%) d 2.067 Price / Cash In Hand g 2.915 Treasury Shares h -
Beta - 75 Daysi 0.353 R-Squared - 75 Days(%)i 2.05 Market Cap (M) 90.129
Beta - 500 Daysi 0.457 R-Squared - 500 Days (%)i 1.30 Enterprise Value (M) 63.361
Piotroski F Score 4 Exchange Code 1J5 Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 33.9123 6-Month VWAP 0.327 Free Float (%) 19.3
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Wholesale and Retail Trade - Pharmaceuticals: Major
Category Classification Medical & Biotechnology
Index Components FTSE ST Catalist Index
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 13 Sep 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Hyphens Pharma SGX 90.129 14.627 14.546 1.8171 2.067
Industry Medical & Biotechnology SGX 1,018.602 18.840 16.097 1.4347 1.919
Pharmaceuticals: Major SGX 90.771 2431.015 115.115 3.7315 0.684
Index FTSE ST Catalist Index SGX 64.648 30.386 23.409 1.4479 1.802
Local Peer IX Biopharma SGX 182.811 - - 8.5069 -
Local Peer Pharmesis Intl SGX 3.105 - - 0.2663 -
Global Peer JOHNSON & JOHNSON NYSE 436,333.560 29.654 24.403 - 2.401
Global Peer PFIZER INC NYSE 244,227.416 25.398 18.463 3.4869 3.488
Global Peer ELI LILLY AND COMPANY NYSE 237,652.984 38.370 39.148 36.8775 1.191
Global Peer MERCK & CO INC NYSE 208,205.182 29.462 37.373 6.2535 3.014
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 206,536.193 25.587 22.989 3.8218 2.272
Global Peer ABBVIE INC NYSE 193,488.538 42.469 29.365 15.3940 4.415
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 192,898.290 60.356 51.153 12.3053 1.865
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 190,284.316 29.530 26.729 18.2002 1.253
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 129,415.686 - - 3.5160 3.190
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 126,245.922 8.993 18.230 1.6834 -
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC CO LTD (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), VIATRIS INC (NASDAQ), REPLIGEN CORP (NASDAQ), HANSOH PHARMACEUTICAL GROUP CO LTD (HKEx), INNOVENT BIOLOGICS INC (HKEx), ORGANON & CO (NYSE), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), CANSINO BIOLOGICS INC (HKEx), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), SINOPHARM GROUP CO. LTD. (HKEx), CUREVAC NV (NASDAQ), REMEGEN CO LTD (HKEx), ALLAKOS INC (NASDAQ), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), HYGEIA HEALTHCARE HLDGS CO LTD (HKEx), HUTCHMED (CHINA) LIMITED (HKEx), SHANGHAI PHARMACEUTICALS HOLDING CO (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), AKESO INC (HKEx), SHANGHAI JUNSHI BIOSCIENCES CO LTD (HKEx), CHINA MEDICAL SYSTEM HLDGS LTD (HKEx), GUANGZHOU BAIYUNSHAN PHARMACEUTICAL (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), INNOCARE PHARMA LTD (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), CHINA RESOURCES PHARMACEUTICAL GR (HKEx), CARSGEN THERAPEUTICS HLDGS LTD (HKEx), NEKTAR THERAPEUTICS (NASDAQ), CHINA GRAND PHARMACEUTICAL & HEALTH (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), SIMCERE PHARMACEUTICAL GRP LTD (HKEx), EMERGENT BIOSOLUTIONS INC (NYSE), OPKO HEALTH INC (NASDAQ), ERASCA INC (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), CHINA TRADITIONAL CHINESE MED HLDGS (HKEx), ATAI LIFE SCIENCES NV (NASDAQ), ADC THERAPEUTICS SA (NYSE), TURNING POINT THERAPEUTICS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), SHANGHAI HENLIUS BIOTECH INC (HKEx), EVEREST MEDICINES LTD (HKEx), DICERNA PHARMACEUTICALS INC. (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), IGM BIOSCIENCES INC (NASDAQ), SHENZHEN HEPALINK PHARMACEUTICAL (HKEx), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), SSY GROUP LIMITED (HKEx), CSTONE PHARMACEUTICALS (HKEx), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), OCUMENSION THERAPEUTICS (HKEx), NURIX THERAPEUTICS INC (NASDAQ), GENERATION BIO CO (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), UNITED LABORATORIES INTL HLDGS LTD (HKEx), Y-MABS THERAPEUTICS INC (NASDAQ), PROCAPS GROUP S A (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), ZYMEWORKS INC (NYSE), IMMUNOTECH BIOPHARM LTD (HKEx), OLEMA PHARMACEUTICALS INC (NASDAQ), BEIJING TONG REN TANG CHINESE MEDIC (HKEx), KINNATE BIOPHARMA INC (NASDAQ), ICOSAVAX INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), Kimia Farma Tbk. (IDX), ABBISKO CAYMAN LTD (HKEx), TENAYA THERAPEUTICS INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), GOSSAMER BIO INC (NASDAQ), KRONOS BIO INC (NASDAQ), SCICLONE PHARMACEUTICALS (HLDGS) LT (HKEx), CULLINAN ONCOLOGY INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), CK LIFE SCIENCES INTL HLDG (HKEx), SUTRO BIOPHARMA INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), ANTENGENE CORP LTD (HKEx), MIND MEDICINE (MINDMED) INC (NASDAQ), GH RESEARCH PLC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), PETIQ INC (NASDAQ), CHINA SHINEWAY PHARMACEUTICAL GR (HKEx), ALIGOS THERAPEUTICS INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), ANNEXON INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), VERU INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), TRANSCENTA HOLDING LTD (HKEx), G1 THERAPEUTICS IN (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), PHARVARIS NV (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), HUA MEDICINE (HKEx), Soho Global Health Tbk. (IDX), MIRUM PHARMACEUTICALS INC (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), ZHAOKE OPHTHALMOLOGY LTD (HKEx), AC IMMUNE SA (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), EVOLUS INC (NASDAQ), IGBB (Bursa), WEREWOLF THERAPEUTICS INC (NASDAQ), PYXIS ONCOLOGY INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), MINK THERAPEUTICS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), PROVENTION BIO INC (NASDAQ), RACE ONCOLOGY LTD (ASX), VERRICA PHARMACEUTICALS INC (NASDAQ), 89BIO INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), CLENE INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), DAWNRAYS PHARMACEUTICAL HLDGS (HKEx), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), TOT BIOPHARM INTL CO LTD (HKEx), STARPHARMA HOLDINGS LIMITED (ASX), SILVERBACK THERAPEUTICS INC (NASDAQ), CYBIN INC (NYSE American), CLEARSIDE BIOMEDICAL INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), FUSION PHARMACEUTICALS INC (NASDAQ), BSTEAD (Bursa), OYSTER POINT PHARMA INC (NASDAQ), NEXIMMUNE INC (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), ATHENEX INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), XOMA CORP (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), HARROW HEALTH INC (NASDAQ), FUSEN PHARMACEUTICAL CO LTD (HKEx), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), PHARMA (Bursa), DURECT CORP (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), TRICIDA INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), IMMUNIC INC (NASDAQ), OBSEVA SA (NASDAQ), ANNOVIS BIO INC (NYSE American), INOZYME PHARMA INC (NASDAQ), MUSTANG BIO INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), IP (SET), TFF PHARMACEUTICALS INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), CHINA BIOTECH SERVICES HLDGS LTD (HKEx), HOOKIPA PHARMA INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), POLYPID LTD (NASDAQ), NOVAN INC (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), NEUBASE THERAPEUTICS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), ZHONGZHI PHARMACEUTICAL HLDGS LTD (HKEx), VTV THERAPEUTICS INC (NASDAQ), ENTERA BIO LTD (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), KALA PHARMACEUTICALS INC (NASDAQ), NOXOPHARM LTD (ASX), APREA THERAPEUTICS INC (NASDAQ), LANNETT CO INC (NYSE), CRESO PHARMA LTD (ASX), KOTRA (Bursa), EDESA BIOTECH INC (NASDAQ), EYENOVIA INC (NASDAQ), MEDIWOUND LTD (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), GENPREX INC (NASDAQ), IMARA INC (NASDAQ), CHARMACY PHARMACEUTICAL CO LTD (HKEx), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), NEW RAY MEDICINE INTL HLDG LTD (HKEx), YUMANITY THERAPEUTICS INC (NASDAQ), PROPHASE LABS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), GALECTO INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), MANNATECH INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), Phapros Tbk. (IDX), ELEDON PHARMACEUTICALS INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), GRAYBUG VISION INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), NOVA (Bursa), PAK FAH YEOW INTERNATIONAL (HKEx), NEW CENTURY HEALTHCARE HLDGS CO LTD (HKEx), AYTU BIOPHARMA INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), ABVC BIOPHARMA INC (NASDAQ), EXOPHARM LTD (ASX), SYNAPTOGENIX INC (NASDAQ), SANAI HEALTH INDUSTRY GP CO LTD (HKEx), INVION LTD (ASX), BIOHLDG (Bursa), WAI YUEN TONG MEDICINE HOLDINGS LTD (HKEx), ACURX PHARMACEUTICALS INC (NASDAQ), MODERN CHINESE MEDICINE GRP CO LTD (HKEx), SHENZHEN NEPTUNUS INTERLONG BIO-TEC (HKEx), UNIVERSE PHARMACEUTICALS INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), BONE BIOLOGICS CORP (NASDAQ), RENOVORX INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), SEQLL INC (NASDAQ), BAUDAX BIO INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), PALLA PHARMA LTD (ASX), MEDLAB CLINICAL LIMITED (ASX), PURAPHARM CORPORATION LIMITED (HKEx), ARIDIS PHARMACEUTICAL INC (NASDAQ), PHARMAXIS (ASX), CNS PHARMACEUTICALS INC (NASDAQ), DERMATA THERAPEUTICS INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), PASITHEA THERAPEUTICS CORP (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), XORTX THERAPEUTICS INC (NASDAQ), VALLON PHARMACEUTICALS INC (NASDAQ), JCT (SET), EXTRAWELL PHARMACEUTICAL HLDGS (HKEx), ONCOSIL MEDICAL LIMITED (ASX), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), SUNZEN (Bursa), TIMBER PHARMACEUTICALS INC (NYSE American), NLS PHARMACEUTICS LTD (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), ACRUX (ASX), PAINREFORM LTD (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), IMMURON LIMITED (ASX), TALI DIGITAL LIMITED (ASX), ISLAND PHARMACEUTICALS LTD (ASX), PETROS PHARMACEUTICALS INC (NASDAQ), NANJING SINOLIFE UNITED COMPANY LTD (HKEx), TITAN PHARMACEUTICAL INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), AROVELLA THERAPEUTICS LTD (ASX), PA SHUN INTERNATIONAL HOLDINGS LTD (HKEx), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.005
+1.69 %
10 Days ---
20 Days --0.010
-3.23 %
Medium Term Return 3 Months --0.015
-4.76 %
6 Months 0.006-0.025
-5.85 %
1 Year 0.006-0.095
-22.53 %
Long Term Return 2 Years 0.016+0.106
+62.89 %
3 Years 0.022+0.085
+49.77 %
Annualised Return Annualised --
+14.41 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.285 - 0.430 Change From 1 Year Low +0.015 % Change From 1 Year Low (%) +5.26
Change From 1 Year High -0.130 % Change From 1 Year High (%) -30.23
2 Years Range 0.180 - 0.625 Change From 2 Years Low +0.120 % Change From 2 Years Low (%) +66.67
Change From 2 Years High -0.325 % Change From 2 Years High (%) -52.00
5 Years Range 0.160 - 0.625 Change From 5 Years Low +0.140 % Change From 5 Years Low (%) +87.50
Change From 5 Years High -0.325 % Change From 5 Years High (%) -52.00
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Hyphens Pharma International Limited and its subsidiaries (the "Group") is one of Singapores leading specialty pharmaceutical and consumer healthcare groups leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in five ASEAN countries, namely, Singapore, Vietnam, Malaysia, Indonesia and the Philippines, supplemented by a marketing and distribution network covering five additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia and Oman. Singapore is the Groups regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based.The Groups core business comprises the following segments: specialty pharma principals, proprietary brands, and medical hypermart and digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

IPO Performance

Listing Date 18 May 2018 Full Subscription Rate (x) 17.91
No of Placement Shares (M) 23.79 No of Public Offer Shares (M) 3.00 Public Offer Subscription Rate (x) 151.99
IPO Price (SGD) a 0.260 First Day Close (SGD) a 0.275 First Week Close (SGD) a 0.260
Current vs IPO Price (%) +15.38 First Day Gain (%) +5.77 First Week Gain (%) -
Notes:
  1. Adjusted for the following: 23,790,000 Placement Shares do not include the 2,810,000 Reserved Shares.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2020 Dec 2020 Part 1(8.67 MB)
Annual Report 2019 Dec 2019 Part 1(6.40 MB)
Annual Report 2018 Dec 2018 Part 1(7.14 MB)
IPO Prospectus
IPO Prospectus 2018 May 2018 Part 1(2.57 MB)
Part 2(0.27 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
26 Oct 2021 0.290 0.295 0.290 0.295 182,900 0.2949
25 Oct 2021 0.290 0.300 0.290 0.300 52,100 0.2907
22 Oct 2021 0.295 0.295 0.295 0.295 5,500 0.2950
21 Oct 2021 0.295 0.295 0.290 0.290 37,200 0.2947
20 Oct 2021 0.295 0.295 0.295 0.295 - -
19 Oct 2021 0.300 0.300 0.295 0.295 106,400 0.2951
18 Oct 2021 0.300 0.300 0.295 0.300 68,500 0.2992
15 Oct 2021 0.300 0.305 0.300 0.305 70,700 0.3000
14 Oct 2021 0.295 0.295 0.295 0.295 20,000 0.2950
13 Oct 2021 0.295 0.295 0.295 0.295 95,100 0.2950
12 Oct 2021 0.300 0.300 0.300 0.300 - -
11 Oct 2021 0.295 0.300 0.295 0.300 202,400 0.2950
08 Oct 2021 0.295 0.300 0.295 0.295 27,500 0.2960
07 Oct 2021 0.290 0.290 0.290 0.290 2,000 0.2900
06 Oct 2021 0.295 0.295 0.290 0.290 105,500 0.2912
05 Oct 2021 0.290 0.295 0.290 0.295 51,000 0.2920
04 Oct 2021 0.295 0.295 0.295 0.295 167,900 0.2950
01 Oct 2021 0.295 0.295 0.295 0.295 - -
30 Sep 2021 0.295 0.295 0.295 0.295 300 0.2950
29 Sep 2021 0.300 0.300 0.295 0.295 31,700 0.2984
28 Sep 2021 0.310 0.310 0.305 0.310 231,000 0.3097
27 Sep 2021 0.295 0.310 0.290 0.310 159,300 0.2975
Summary
Current 2 Weeks
(13 Oct 2021 to 26 Oct 2021)
0.295 0.305 0.290 0.295 638,400 -
Previous 2 Weeks
(29 Sep 2021 to 12 Oct 2021)
0.300 0.305 0.290 0.300 588,300 -
4 Weeks from
(01 Sep 2021 to 28 Sep 2021)
0.300 0.305 0.290 0.310 1,391,700 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.